The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.

The present disclosure relates to a method for diagnosing mood disorder such as mania, depression and mania mixed using a circadian rhythm. According to the diagnostic method of the present disclosure, the condition of mood disorder can be diagnosed objectively and clearly based on the advance or delay of the circadian rhythm. That is to say, hypomania, mania, depression, mixed mania, etc. may be determined quickly and adequately so that appropriate therapeutic intervention can be made. In addition, according to the diagnostic method of the present disclosure, schizophrenia which is frequently confused with severe depression or bipolar disorder can be distinguished clearly. In addition, the selection of a therapeutic drug can be benefited greatly through this.

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V.sub.H, V.sub.L, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

A multi-analyte sensor includes a body having a proximal end and a distal end. A plurality of strips is connected to one end of the body and a plurality of electrical conductors run through the body and into the plurality of strips. Exposed portions of first and second electrical conductors running through first and second strips are coated with analyte-responsive materials, such as a first molecular imprinted polymer (MIP) and a second MIP, respectively. The first MIP has binding sites for a first target analyte and the second MIP has binding sites for a second target analyte. The multi-analyte sensor may be part of a sensing device that also includes a controller and a data store.

Disclosed herein is the use of copeptin as a diagnostic marker for the determination of the release of vasopressin, especially in connection with disorders associated with non-physiological alterations of vasopressin release from the neurohypophysis, especially for detection and early detection, diagnosing and monitoring of the course of cardiovascular diseases, renal and pulmonary diseases as well as shock, including septic shock, sepsis and diseases/disorders of the central nervous system and neurodegenerative diseases.

A method for determining the likelihood of an ectopic pregnancy and spontaneous miscarriage is described, by measuring the levels of markers, especially hCG and CA-125 which have been found to be characteristic of these conditions. Preferably measuring these biomarker levels at earliest possible presentation of patients with general clinical symptoms and applying cut-off values described determines the likelihood of an ectopic pregnancy and spontaneous miscarriage.

The invention relates to methods for determining the likelihood that a patient with mild cognitive impairment develops Alzheimer's disease based on the determination of the levels of different metabolites, including amino acids, proteins and lipids. The invention also provides a method for diagnosing Alzheimer's disease or mild cognitive impairment in a subject based on the determination of the above metabolites.

The subject technology is directed to a CO.sub.2-based chromatography system and method for rapid determination of the levels and/or the presence or absence of steroids or steroid derivatives in a sample.

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Method of diagnosis of IVF viability. The method includes ascertaining a subject's AMH level from testing and then selecting one pregnancy or live birth prognosis category that applies to the ascertained AMH level by matching the ascertained AMH level with an applicable one of a plurality of ranges of AMH levels pertaining to an age of the subject. The matching indicates the prognosis category that applies, i.e., (that is, good, intermediate or poor. In view of the diagnosis, a method of administration of AMH may be pursued to increase probability of pregnancy or live birth chances. Alternatively, the administration of AMH may be at AMH levels that will terminate pregnancy or increase the chance of miscarriage.